Hitachi Announces NVIDIA AI Factory to Accelerate Physical AI Innovation
26.9.2025 04:00:00 CEST | Business Wire | Press Release
Hitachi, Ltd. (TSE:6501, "Hitachi"), today announced the establishment of a global Hitachi AI Factory based on NVIDIA AI Factory reference architecture, yielding a centralized infrastructure designed to accelerate the development and deployment of physical AI solutions across Hitachi’s core business sectors. The AI Factory is powered by Hitachi iQ with NVIDIA HGX B200 systems featuring NVIDIA Blackwell GPUs; Hitachi iQ M Series with NVIDIA RTX PRO 6000 Server Edition GPUs; and NVIDIA Spectrum-X Ethernet networking platform. This strategic initiative directly supports Hitachi's ambition to create and deploy AI that interacts with the real world. The AI Factory will also enable Hitachi to further expand HMAX—the company’s family of AI-enabled solutions solving a wide-range of complex problems in the Mobility, Energy, Industrial and Technology sectors.
The centralized AI Factory provides Hitachi’s global teams with a powerful unified AI computing infrastructure to run applications and AI workflows developed on the NVIDIA full-stack AI platform, which includes NVIDIA AI Enterprise for production-grade AI as well as NVIDIA Omniverse libraries for simulation, industrial scale, and physically accurate digital twins. This infrastructure allows for the rapid development and deployment of advanced physical AI models. These models will acquire and interpret information from physical environments via cameras and sensors; determine the next steps to take; and execute actions based on that data.
Today’s announcement builds on Hitachi, Ltd. President and CEO Toshiaki Tokunaga’s recent comment on the Hitachi-NVIDIA partnership wherein he stated that, by leveraging Hitachi iQ built on NVIDIA RTX PRO Servers, Hitachi will further accelerate AI innovation. Mr. Tokunaga specified that through the NVIDIA RTX PRO Servers’ ability to accelerate AI reasoning and physical AI, digital twin development and physical asset optimization (including social infrastructure) is augmented while new possibilities such as productivity improvement across all business activities are unlocked.
The Hitachi AI Factory is strategically distributed across the United States, EMEA, and Japan ensuring that Hitachi’s engineers can collaborate seamlessly and access powerful computing resources with low latency, no matter where they are. This interconnected network will support the creation of a wide range of physical AI applications, driving new levels of efficiency, productivity, and safety across industries.
The initiative reinforces Hitachi's commitment to using cutting-edge technology to drive both social and business innovation.
“The strategic collaboration between Hitachi and NVIDIA is becoming a key engine for solving complex real-world problems, accelerating social innovation,” said Jun Abe, General Manager of the Digital Systems & Services Division. “Our work together leverages NVIDIA AI infrastructure to achieve both DX (Digital Transformation) and GX (Green Transformation) with solutions like Hitachi Rail's HMAX, which is currently transforming railway operations and maintenance; Hitachi Vantara's AI solution portfolio Hitachi iQ; and Hitachi's liquid-cooled AI data centers supporting our generative AI foundation. By establishing a global NVIDIA AI Factory, we can now operate as a true 'One Hitachi' across regions and organizations. A synergy that will accelerate physical AI innovations, as exemplified by HMAX.”
Operationalizing the Corporate Vision
Hitachi views the AI Factory as a fundamental step toward achieving its Lumada 3.0 vision. Lumada is Hitachi’s operating model that helps enterprises solve business and societal problems through co-created digital transformation. It harnesses Hitachi’s extensive domain knowledge and technical expertise, combined with AI technologies to convert data into value while reducing operational costs and inefficiencies.
Hitachi is unique in its ability to integrate IT, OT, and hardware expertise as illustrated by the engineering design capabilities, products, and consultative services making up Lumada 3.0. The company leads the Industrial AI market with disruptive solutions that redefine what’s possible.
“AI factories are the engines of a new industrial revolution, converting enterprise data into autonomous intelligence for both software and the physical world,” said Justin Boitano, Vice President, Enterprise AI Products, NVIDIA. “With NVIDIA accelerated computing and software, Hitachi’s AI factory infrastructure provides a transformative platform for building and deploying enterprise and physical AI.”
About Hitachi, Ltd.
Through its Social Innovation Business (SIB) that brings together IT, OT(Operational Technology) and products, Hitachi contributes to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates globally in four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – and the Strategic SIB Business Unit for new growth businesses. With Lumada at its core, Hitachi generates value from integrating data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2024 (ended March 31, 2025) totaled 9,783.3 billion yen, with 618 consolidated subsidiaries and approximately 280,000 employees worldwide. Visit us at www.hitachi.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250925584517/en/
Contacts
Media Contacts
Hiroko Motomura
Hitachi, Ltd.
hiroko.motomura.qc@hitachi.com
Heather Ailara
Hitachi Digital (North America and Europe)
heather@211comms.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom